Virax Biolabs Group Limited announced that it has signed contracts to launch two new research and laboratory facilities in the United Kingdom. The Company has signed a contract to launch a laboratory facility at Scale Space. Scale Space is conveniently located in a major metropolitan hub in the heart of the unique innovation ecosystem at Imperial College London, a 23-acre research and innovation district in White City, west London.

The facility includesphlebotomy stations, laboratories and research facilities, and offers access to cutting-edge resources and networking opportunities, acting as a catalyst for transforming ground-breaking ideas into practical applications, and empowering organizations to make a lasting impact on society. If granted approval by the regulatory agencies, the site would be instrumental in the initial launch of ViraxImmune, acting as the first laboratory for blood draw and analysis. The laboratory would also give the Company the ability to fulfill third party laboratory orders.

The UK-based laboratory provides a scalable infrastructure while avoiding the requirement for complex processes and expensive lab equipment. Additionally, Virax has signed a lease agreement with BioCity Glasgow to establish a research laboratory in Glasgow, United Kingdom. The facility is within proximity to top-ranked institutions including the Universities of Glasgow and Edinburgh, and major hospitals and clinics in Scotland.

This convenient location facilitates close cooperation with the National Health Service, access to fresh blood samples and blood banks for ongoing and future assessments, and collaborations with local research groups specialized in immunology. As part of BioCity, the Company will have access to cost-effective community facilities, and more broadly, access to a number of additional communities of experts based in incubators across the UK Science Parks Association and the United Kingdom. Establishment of a facility in Glasgow extends research capacity, enabling to simultaneously and independently develop multiple new products within ViraxImmune platform from early to late stage, including verification and validation, James Foster, Virax's Chairman of the Board of Directors and Chief Executive Officer.